Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
2020 · Leukemia · 240 citations
https://doi.org/10.1038/s41375-020-01072-6
P
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
43
Papers
901
Citations
13
h-index
20
i10-index
Peng Liu is an academic researcher from Chinese Academy of Medical Sciences & Peking Union Medical College. The author has contributed to research in topics: Lymphoma Diagnosis and Treatment & Viral-associated cancers and disorders & Chronic Lymphocytic Leukemia Research. The author has an h-index of 13, co-authored 37 publications.
ORCID: 0000-0001-6129-6325Papers by this author
worksPositive Regulation of Interleukin-1β Bioactivity by Physiological ROS-Mediated Cysteine S-Glutathionylation
2017 · Cell Reports · 43 citations
https://doi.org/10.1016/j.celrep.2017.05.070
Comparison of CBV, BEAM and BEAC high‐dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non‐Hodgkin lymphoma: Efficacy and toxicity
2017 · Asia-Pacific Journal of Clinical Oncology · 25 citations
https://doi.org/10.1111/ajco.12610
E17110 promotes reverse cholesterol transport with liver X receptor β agonist activity in vitro
2016 · Acta Pharmaceutica Sinica B · 12 citations
https://doi.org/10.1016/j.apsb.2016.03.005
Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era
2022 · BMC Cancer · 12 citations
https://doi.org/10.1186/s12885-022-09693-z
Comparing the efficacy and safety of first-line treatments for chronic lymphocytic leukemia: a network meta-analysis
2024 · JNCI Journal of the National Cancer Institute · 3 citations
https://doi.org/10.1093/jnci/djae245
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat